180 Life Sciences Corp. Files Q1 2025 10-Q

Ticker: FRMM · Form: 10-Q · Filed: May 15, 2025 · CIK: 1690080

180 Life Sciences CORP. 10-Q Filing Summary
FieldDetail
Company180 Life Sciences CORP. (FRMM)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

180 Life Sciences filed its Q1 2025 10-Q. Check financials.

AI Summary

180 Life Sciences Corp. filed its quarterly report (10-Q) for the period ending March 31, 2025. The company, formerly known as KBL Merger Corp. IV, is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Palo Alto, California.

Why It Matters

This filing provides investors with an update on 180 Life Sciences Corp.'s financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing providing basic company information and reporting period details.

Key Players & Entities

FAQ

What is the primary business of 180 Life Sciences Corp.?

180 Life Sciences Corp. operates in the Pharmaceutical Preparations sector, with the Standard Industrial Classification code 2834.

When was the company formerly known as?

The company was formerly known as KBL Merger Corp. IV, with a date of name change on November 15, 2016.

In which state is 180 Life Sciences Corp. incorporated?

180 Life Sciences Corp. is incorporated in Delaware.

What is the address of the principal executive offices?

The principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.

What is the SEC file number for 180 Life Sciences Corp.?

The SEC file number for 180 Life Sciences Corp. is 001-38105.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding 180 Life Sciences Corp. (FRMM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing